multiple myeloma
Item
all patients must have a confirmed diagnosis of previously treated, active multiple myeloma
boolean
C0026764 (UMLS CUI [1])
myeloma protein
Item
myeloma protein should be evident from which to evaluate response
boolean
C0027015 (UMLS CUI [1])
age, contraception
Item
must be 18 years of age or older. women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
boolean
C0001779 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
informed consent
Item
patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
boolean
C0021430 (UMLS CUI [1])
white blood cell count
Item
patients must have a total white blood cell count of 2,000 k/microliters. patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
boolean
C0023508 (UMLS CUI [1])
liver function
Item
patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dl.
boolean
C1278039 (UMLS CUI [1])
active infection
Item
patients must not have an active infection requiring parenteral antibiotics
boolean
C0009450 (UMLS CUI [1])
concurrent therapy
Item
no other concurrent therapy for myeloma is permitted while on thalidomide
boolean
C0039736 (UMLS CUI [1])